Last month, Shire said it still believed an acquisition for Baxalta--a target that rejected it almost four months back--would make a "highly strategic combination." And now, it's preparing to follow up.
Pfizer may be amped about its brand-new agreement to tie up with Allergan and move to tax-advantaged Ireland. But U.S. politicians? They're not so thrilled with the idea. Read more >>
The agreement's been made: The boards at Pfizer and Allergan have ratified a megamerger--worth about $160 billion--that will create the world's biggest pharma company and send Pfizer overseas, the companies announced on Monday. Read more >>
Four months after stepping aside as R&D chief at Biogen, Doug Williams announced this week that he signed on over the summer to lead startup Codiak Biosciences, which will set out to explore the role exosomes play in treating cancer and other diseases. Read more >>
POPULAR COMMENT THREADS
Good-bye appointment TV, hello TV everywhere. As TV and video watching becomes wherever and whenever consumers want, marketers, including pharma, have had to shift strategies to reach those hard-to-pin-down viewers.
Read more from FiercePharmaMarketing >>
Turing Pharmaceuticals promised to lower the price of its toxoplasmosis med, Daraprim, in response to growing backlash from lawmakers and the public after it bought the drug in August and jacked up its price by more than 5000%. Now the company is opting to negotiate discounts with hospitals rather than cut the drug's list price.
Denmark's Xellia Pharmaceuticals has bought the former Ben Venue plant, at one time the most notorious U.S. plant under FDA supervision, a facility responsible for dozens of recalls and a slew of drug shortages.
Earlier this month, Perrigo shareholders spurned a hostile buyout attempt from Mylan. And now, the Netherlands-based company may have to go up against its former target if it wants to pursue a replacement buy.
An FDA warning letter found that for years, Dr. Reddy's Laboratories was testing drug batches in a laboratory that the FDA was never told existed and often shipped to the U.S. products that had repeatedly failed tests for impurities.
Amgen's multiple myeloma treatment Kyprolis finally won approval in Europe--and with competition heating up across the pond, the go-ahead couldn't have come at a better time.
From Our Sister Sites
Siemens plans 7,000+ layoffs after disappointing healthcare performance Following a 13% reduction in profit at Siemens Healthcare during the previous quarter, the conglomerate is reportedly planning...
Sweden's Lund University is forming a med tech accelerator with an emphasis on digital health.